Nycomed to launch single dose Instanyl in September 2011
This article was originally published in Scrip
Executive Summary
Nycomed is to launch its Instanyl (fentanyl) single-dose nasal spray for the management of breakthrough pain in cancer patients in Europe from September this year after receiving marketing authorisation from the EMA.